153 related articles for article (PubMed ID: 29245078)
1. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
[TBL] [Abstract][Full Text] [Related]
2. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
5. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Schadendorf D; Ascierto PA; Arance A; Dutriaux C; Di Giacomo AM; Rutkowski P; Del Vecchio M; Gutzmer R; Mandala M; Thomas L; Demidov L; Garbe C; Hogg D; Liszkay G; Queirolo P; Wasserman E; Ford J; Weill M; Sirulnik LA; Jehl V; Bozón V; Long GV; Flaherty K
Lancet Oncol; 2017 Apr; 18(4):435-445. PubMed ID: 28284557
[TBL] [Abstract][Full Text] [Related]
6. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
[TBL] [Abstract][Full Text] [Related]
8.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
9. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
10. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
11. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
12. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
[TBL] [Abstract][Full Text] [Related]
13. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Vu HL; Aplin AE
Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
[TBL] [Abstract][Full Text] [Related]
14. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
15. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
16. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract][Full Text] [Related]
17. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
[TBL] [Abstract][Full Text] [Related]
18. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
19. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
20. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]